24 June 2024

cyclomedica
technegas

Cyclopharm Ltd
ABN 74 116 931 250
Unit 4, 1 The Crescent
Kingsgrove NSW 2208 Australia
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

TECHNEGAS AWARDED MAXIMUM THREE YEAR TRANSITIONAL PASS-THROUGH REIMBURSEMENT STATUS IN THE US

Cyclopharm (ASX:CYC) today announced it has received further information from the Center for Medicare and Medicade Services (CMS) related to the Transitional Pass-Through (TPT) reimbursement status for Technegas awarded and announced on 5 June 2024. Referenced in the CMS quarterly update to US healthcare provides, commencing from 1 July 2024:

- **Technegas will receive Transitional Pass-Through reimbursement status for 3 years, the maximum period allowed under the TPT program and confirmation**
- **That the TPT awarded rate will be sufficient to fully reimburse users for the use of Technegas**

The Importance of Transitional Pass-Through Status:

Transitional Pass-Through (TPT) status for Technegas for three years is significant for several reasons:

1. **Reimbursement:** TPT status allows Technegas to be reimbursed separately from the procedures with which it is used. This will lead to higher overall reimbursement and better financial incentives for healthcare providers using Technegas.
2. **Market Access:** TPT status is expected to expedite market penetration by promoting quicker adoption of Technegas into clinical practice. In general, TPT encourages hospitals to adopt and use new technologies that have shown promise in improving patient outcomes or efficiency of care. This is particularly relevant as Technegas is known to offer improved clinical outcomes, a better patient experience and operational benefits over other competing nuclear medicine products.
3. **Patient Access:** TPT will improve patient access and encourage healthcare providers to adopt Technegas without concerns about financial feasibility.
4. **Competitive Advantage:** Being early adopters of innovative technologies like Technegas can enhance a hospital's reputation for offering cutting-edge care, attracting referrals from clinicians seeking improved diagnostic and patient treatment options

Cyclopharm CEO James McBrayer said, "We are extremely pleased with the additional information provided by CMS. The clinical superiority of Technegas over competing products are well established and with TPT, users now have both the clinical motivation and financial incentive to implement Technegas."

"In line with clinical guidelines in Europe and Canada, the adoption of Technegas in the United States, facilitated by reimbursement, is also expected to advance the introduction of 3-D SPECT and SPECT/CT imaging, which are techniques superior to the 2-D imaging predominantly used in the USA. This advancement is expected to allow nuclear medicine to compete for market share currently held by CTPA, as well as facilitating Beyond Pulmonary Embolism applications," Mr McBrayer said.

- ENDS -

This ASX announcement was approved and authorised for release by James McBrayer, Managing Director and CEO.

For more information, please contact:

Mr James McBrayer
Managing Director, CEO and Company Secretary
Cyclopharm Limited
T: +61 (02) 9541 0411

Cyclopharm Limited
Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas® used in functional lung ventilation imaging.

Technegas®
The Technegas® technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700° C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas®, together with advancements in complementary technology to multimodality imaging and analytical software, is being used in other disease states to include COPD, asthma, pulmonary hypertension, Long COVID and certain interventional applications to include lobectomies in lung cancer and lung volume reduction surgery.

In the United States the Technegas approved indication for use for use is:
TECHNEGAS, when used with sodium pertechnetate Tc 99m in the Technegas Plus System, provides technetium Tc 99m-labeled carbon inhalation aerosol (Technegas Aerosol), a radioactive diagnostic agent for use in adults and pediatric patients aged 6 years and older is for the visualization of pulmonary ventilation and the evaluation of pulmonary embolism when paired with perfusion imaging.